Klaria Pharma Holding AB (publ.) (KLAR.ST)

SEK 0.29

(-8.63%)

Market Cap (In SEK)

41.4 Million

Revenue (In SEK)

-

Net Income (In SEK)

-35.78 Million

Avg. Volume

736.5 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.14-1.145
PE
-
EPS
-
Beta Value
0.443
ISIN
SE0007280326
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Scott Boyer
Employee Count
-
Website
https://www.klaria.com
Ipo Date
2015-10-21
Details
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.